A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability
© 2022. The Author(s)..
mRNA vaccines were the first to be authorized for use against SARS-CoV-2 and have since demonstrated high efficacy against serious illness and death. However, limitations in these vaccines have been recognized due to their requirement for cold storage, short durability of protection, and lack of access in low-resource regions. We have developed an easily-manufactured, potent self-amplifying RNA (saRNA) vaccine against SARS-CoV-2 that is stable at room temperature. This saRNA vaccine is formulated with a nanostructured lipid carrier (NLC), providing stability, ease of manufacturing, and protection against degradation. In preclinical studies, this saRNA/NLC vaccine induced strong humoral immunity, as demonstrated by high pseudovirus neutralization titers to the Alpha, Beta, and Delta variants of concern and induction of bone marrow-resident antibody-secreting cells. Robust Th1-biased T-cell responses were also observed after prime or homologous prime-boost in mice. Notably, the saRNA/NLC platform demonstrated thermostability when stored lyophilized at room temperature for at least 6 months and at refrigerated temperatures for at least 10 months. Taken together, this saRNA delivered by NLC represents a potential improvement in RNA technology that could allow wider access to RNA vaccines for the current COVID-19 and future pandemics.
| Errataetall: |
ErratumIn: NPJ Vaccines. 2022 Nov 23;7(1):150. - PMID 36418864 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
NPJ vaccines - 7(2022), 1 vom: 02. Nov., Seite 136 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Voigt, Emily A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 30.11.2022 published: Electronic ErratumIn: NPJ Vaccines. 2022 Nov 23;7(1):150. - PMID 36418864 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1038/s41541-022-00549-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348376359 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348376359 | ||
| 003 | DE-627 | ||
| 005 | 20231226040028.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41541-022-00549-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1161.xml |
| 035 | |a (DE-627)NLM348376359 | ||
| 035 | |a (NLM)36323666 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Voigt, Emily A |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.11.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ErratumIn: NPJ Vaccines. 2022 Nov 23;7(1):150. - PMID 36418864 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a mRNA vaccines were the first to be authorized for use against SARS-CoV-2 and have since demonstrated high efficacy against serious illness and death. However, limitations in these vaccines have been recognized due to their requirement for cold storage, short durability of protection, and lack of access in low-resource regions. We have developed an easily-manufactured, potent self-amplifying RNA (saRNA) vaccine against SARS-CoV-2 that is stable at room temperature. This saRNA vaccine is formulated with a nanostructured lipid carrier (NLC), providing stability, ease of manufacturing, and protection against degradation. In preclinical studies, this saRNA/NLC vaccine induced strong humoral immunity, as demonstrated by high pseudovirus neutralization titers to the Alpha, Beta, and Delta variants of concern and induction of bone marrow-resident antibody-secreting cells. Robust Th1-biased T-cell responses were also observed after prime or homologous prime-boost in mice. Notably, the saRNA/NLC platform demonstrated thermostability when stored lyophilized at room temperature for at least 6 months and at refrigerated temperatures for at least 10 months. Taken together, this saRNA delivered by NLC represents a potential improvement in RNA technology that could allow wider access to RNA vaccines for the current COVID-19 and future pandemics | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Gerhardt, Alana |e verfasserin |4 aut | |
| 700 | 1 | |a Hanson, Derek |e verfasserin |4 aut | |
| 700 | 1 | |a Jennewein, Madeleine F |e verfasserin |4 aut | |
| 700 | 1 | |a Battisti, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Reed, Sierra |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Jasneet |e verfasserin |4 aut | |
| 700 | 1 | |a Mohamath, Raodoh |e verfasserin |4 aut | |
| 700 | 1 | |a Bakken, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Beaver, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Press, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Soon-Shiong, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Paddon, Christopher J |e verfasserin |4 aut | |
| 700 | 1 | |a Fox, Christopher B |e verfasserin |4 aut | |
| 700 | 1 | |a Casper, Corey |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t NPJ vaccines |d 2016 |g 7(2022), 1 vom: 02. Nov., Seite 136 |w (DE-627)NLM273825623 |x 2059-0105 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2022 |g number:1 |g day:02 |g month:11 |g pages:136 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41541-022-00549-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2022 |e 1 |b 02 |c 11 |h 136 | ||